BTMD biote Corp.
HealthcareAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
2.59
PEG
0.00
P/B
-1.09
P/S
0.47
EV/EBITDA
5.34
DCF Value
$3.86
FCF Yield
32.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
68.5%
Operating Margin
17.0%
Net Margin
8.3%
ROE
-22.9%
ROA
17.5%
ROIC
37.1%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $44.9M | $2.3M | $— |
| Q4 null | $46.4M | $2.0M | $— |
| FY null | $192.2M | $27.0M | $— |
| Q3 null | $48.0M | $8.2M | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$3.25
Target (Median)
$3.25
Target Range
$2.50 - $4.00
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
Medical - Care Facilities
Country
US
Exchange
—
Beta
1.71
biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.